Shandong Jincheng Pharmaceutical Group Co., Ltd (SHE:300233)
China · Delayed Price · Currency is CNY 15.12
-0.17 (-1.11%)
At close: Feb 13, 2026
SHE:300233 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 77.3 | 196.78 | 174.71 | 273.37 | 107.98 | -488.84 |
Depreciation & Amortization | 319.26 | 319.26 | 308.17 | 255.77 | 224.03 | 198.05 |
Other Amortization | 3.51 | 3.51 | 3.49 | 3.01 | 9.46 | 17.51 |
Loss (Gain) From Sale of Assets | -1.45 | -1.45 | 2.16 | -1.53 | -1.02 | -0.43 |
Asset Writedown & Restructuring Costs | 14.53 | 14.53 | 2.49 | 21.32 | 39.07 | 746.2 |
Loss (Gain) From Sale of Investments | 1.67 | 1.67 | -0.59 | 8.68 | -12.5 | -0.32 |
Provision & Write-off of Bad Debts | -2.49 | -2.49 | 2.77 | -0.08 | -4.52 | 19.29 |
Other Operating Activities | 144.7 | 42.48 | 88.03 | 50.91 | 78.41 | 43.79 |
Change in Accounts Receivable | -28.11 | -28.11 | -124.9 | -314.2 | -89.1 | -22.34 |
Change in Inventory | -115.59 | -115.59 | 32.08 | -202.78 | -133.37 | -40.64 |
Change in Accounts Payable | -137.11 | -137.11 | 213.55 | 127.52 | 194.72 | 84.19 |
Change in Other Net Operating Assets | - | - | -16.46 | 21.35 | - | - |
Operating Cash Flow | 279.33 | 296.59 | 664.08 | 255.63 | 437.19 | 546.13 |
Operating Cash Flow Growth | -30.96% | -55.34% | 159.78% | -41.53% | -19.95% | -5.51% |
Capital Expenditures | -104.88 | -142.61 | -342.9 | -373.67 | -376.14 | -272.44 |
Sale of Property, Plant & Equipment | 11.7 | 62.29 | 24.86 | 6.48 | 5.67 | 2.39 |
Divestitures | - | - | - | -0.96 | - | - |
Investment in Securities | - | -4 | 10 | 3.9 | 129.1 | -166 |
Other Investing Activities | -21.61 | 0.01 | -1.95 | 6.42 | 9.84 | -14.9 |
Investing Cash Flow | -114.79 | -84.32 | -309.99 | -357.82 | -231.54 | -450.95 |
Long-Term Debt Issued | - | 239 | 348.37 | 475.97 | 383.7 | 431.39 |
Long-Term Debt Repaid | - | -283.38 | -449.03 | -418.99 | -390.7 | -463.9 |
Net Debt Issued (Repaid) | -219.07 | -44.38 | -100.66 | 56.98 | -7 | -32.51 |
Issuance of Common Stock | - | - | - | 56.94 | - | - |
Repurchase of Common Stock | -55.01 | -55.01 | - | - | -80.01 | -59.59 |
Common Dividends Paid | -163.85 | -131.67 | -83.52 | -104.78 | -105.19 | -100.87 |
Other Financing Activities | 54.78 | -12.71 | -59.13 | -5.31 | 0.54 | 0.48 |
Financing Cash Flow | -383.14 | -243.77 | -243.31 | 3.83 | -191.66 | -192.49 |
Foreign Exchange Rate Adjustments | 3.69 | 5.96 | 3.47 | 4.3 | -4.97 | -5.06 |
Net Cash Flow | -214.91 | -25.54 | 114.24 | -94.07 | 9.01 | -102.37 |
Free Cash Flow | 174.45 | 153.97 | 321.18 | -118.04 | 61.04 | 273.69 |
Free Cash Flow Growth | 22.78% | -52.06% | - | - | -77.70% | 26.52% |
Free Cash Flow Margin | 6.25% | 4.56% | 9.08% | -3.37% | 1.94% | 9.24% |
Free Cash Flow Per Share | 0.45 | 0.41 | 0.83 | -0.31 | 0.16 | 0.70 |
Cash Income Tax Paid | 169.89 | 172.91 | 155.47 | 114.1 | 151.12 | 170.55 |
Levered Free Cash Flow | 218.36 | 16.33 | 251.22 | 115.33 | 9.67 | 434.43 |
Unlevered Free Cash Flow | 226.15 | 27.88 | 266.8 | 132.09 | 26.57 | 449 |
Change in Working Capital | -277.69 | -277.69 | 82.85 | -355.82 | -3.72 | 10.9 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.